Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Oct 28, 2024 · CIK: 1581178
Sentiment: neutral
Topics: sec-filing, 6-K, press-release
Related Tickers: EPRX
TL;DR
Eupraxia Pharma (EPRX) filed a 6-K on Oct 28th with a press release attached. Check it for updates.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 28, 2024, reporting information for the month of October 2024. The filing includes Exhibit 99.1, which is a press release dated October 28, 2024. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' activities and may contain important information for investors regarding the company's operations and disclosures.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- October 28, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- 201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 (address) — Principal executive office
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public in its home country, files or makes public with a stock exchange, or distributes or makes public to its security holders.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated October 28, 2024, is included as part of this report.
What is Eupraxia Pharmaceuticals Inc.'s principal executive office address?
The principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
The report was signed by Bruce Cousins on behalf of Eupraxia Pharmaceuticals Inc.
What is the SEC file number for Eupraxia Pharmaceuticals Inc.?
The SEC file number for Eupraxia Pharmaceuticals Inc. is 001-41923.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-10-28 07:02:08
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 18KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001270.txt ( ) — 62KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: October 28, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer